Myriad Genetics (MYGN) Announces Submission of BRACAnalysis CDx Test for Approval in Japan

November 7, 2016 7:17 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Myriad Genetics, Inc. (Nasdaq: MYGN) announced that it will submit its BRACAnalysis CDx test for approval by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in parallel with the PMDA review of AstraZeneca’s novel PARP inhibitor, olaparib.

BRACAnalysis CDx is the leading genetic test to identify patients who are likely to benefit from treatment with olaparib, which is a novel PARP inhibitor that targets tumor DNA repair pathway deficiencies to preferentially kill cancer cells.

"BRACAnalysis CDx launched precision medicine for ovarian cancer patients by identifying patients more likely to respond to PARP inhibitors," said Mark C. Capone, president and CEO, Myriad Genetics. "As a global leader in personalized medicine, Myriad is committed to providing the highest quality molecular tests in the fight against the world's most challenging diseases, including breast and ovarian cancers."

Today’s announcement builds on a long-term companion diagnostic collaboration with AstraZeneca that began in 2007. In December 2014, the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx to identify ovarian cancer patients who may be appropriate for treatment with Lynparza™ (olaparib). It was the first time the FDA had approved a laboratory developed test (LDT) under the premarket approval application process.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Related Entities

Definitive Agreement

Add Your Comment